HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA tobacco oversight bill passes to President

This article was originally published in The Rose Sheet

Executive Summary

Bipartisan legislation giving FDA regulatory responsibility over production, sale and marketing of tobacco products passes House June 12 after clearing Senate the day before. The Family Smoking Prevention and Tobacco Control Act moves next to the White House for signature promised by President Obama. H.R. 1256 requires agency to establish a Center for Tobacco Products within 90 days upon enactment of the law. Counting FDA's Center for Toxicological Research, tobacco brings total number of FDA centers to seven. User fees will fund program; legislators behind the bill maintain resources will not be diverted from other activities

You may also be interested in...



New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy

The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel